Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Januvia (sitagliptin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• This summary is based on the review of 11 systematic review(s)/meta-analysis(es). ^[1-11]
• LADA Patients (Sitagliptin + Insulin vs. Insulin Alone): Sitagliptin combined with insulin resulted in a reduction of HbA1c (WMD -0.36, 95% CI -0.61 to -0.10) and an increase in fasting C-peptide (WMD 0.08, 95% CI -0.02 to 0.17).
• T2DM Patients (Semaglutide vs. Sitagliptin): Semaglutide, compared to sitagliptin, led to a greater reduction in HbA1c (WMD -0.98, 95% CI -1.28 to -0.69), with additional benefits in systolic and diastolic blood pressure, body weight, and waist circumference.
• T2DM Patients (Dual vs. Single Oral AHAs): Dual therapy with ertugliflozin and sitagliptin showed greater HbA1c reduction and significant decreases in body weight and systolic blood pressure compared to single-agent DPP-4 inhibitors.
• Overweight/Obese T2DM Patients (Sitagliptin vs. GLP-1 Receptor Agonists): Sitagliptin was less effective than GLP-1 receptor agonists in reducing HbA1c, fasting plasma glucose, and postprandial glucose.
• In LADA patients, the combination of sitagliptin and insulin resulted in fewer adverse events and a lower incidence of hypoglycemia compared to insulin alone.
• In T2DM patients, semaglutide was associated with a higher risk of total adverse events and treatment discontinuation compared to sitagliptin, though there were no significant differences in serious, severe, moderate, and mild adverse events.
• Across various T2DM populations, sitagliptin showed a comparable safety profile to other treatments, with no significant increases in hypoglycemia or other severe adverse events.
• The reviewed study contains population and subgroup information specific to LADA patients, T2DM patients on metformin, T2DM patients using premixed insulin, and overweight/obese T2DM patients.